Untaaveesup Suvijak, Srichana Pornteera, Techataweewan Gynna, Pongphaew Chanamon, Dendumrongsup Wichapol, Ponvilawan Ben, Nampipat Nichanant, Limwongse Chanin
Chao Khun Paiboon Hospital, Kanchanaburi, Thailand.
Detudom Crown Prince Hospital, Ubon Ratchathani, Thailand.
Ann Med. 2025 Dec;57(1):2516701. doi: 10.1080/07853890.2025.2516701. Epub 2025 Jun 16.
Basal cell carcinoma (BCC) is a prevalent form of skin cancer that can be localized or metastatic. Current evidence supports the use of Hedgehog (Hh) pathway inhibitors for locally advanced or metastatic BCC with resistance due to genetic alterations in the Hh pathway. This systematic review evaluated the prevalence of genetic alterations in Hh pathway genes in BCC.
We conducted a comprehensive search across four databases: PubMed, EMBASE, SCOPUS and the Cochrane Library. We included articles reporting genetic alterations in patients with locally advanced or metastatic BCC resistant to Hh pathway inhibitors.
We included three prospective cohort studies encompassing 27 samples, all of which were resistant to vismodegib treatment. The most prevalent genetic mutations in the Hh pathway were in , and , with a pooled prevalence of 44.44%.
This systematic review highlights the prevalence of genetic alterations in the Hh pathway in BCC and offers insights into the mechanisms involved in treatment resistance. Understanding the high resistance rates of these genes may facilitate the development of more effective targeted therapies for BCC.
基底细胞癌（BCC）是一种常见的皮肤癌形式，可局限或转移。目前的证据支持使用刺猬（Hh）通路抑制剂治疗因Hh通路基因改变而耐药的局部晚期或转移性BCC。本系统评价评估了BCC中Hh通路基因改变的患病率。
我们在四个数据库中进行了全面检索：PubMed、EMBASE、SCOPUS和Cochrane图书馆。我们纳入了报告对Hh通路抑制剂耐药的局部晚期或转移性BCC患者基因改变的文章。
我们纳入了三项前瞻性队列研究，共27个样本，所有样本均对维莫德吉治疗耐药。Hh通路中最常见的基因突变位于 、 和 ，合并患病率为44.44%。
本系统评价突出了BCC中Hh通路基因改变的患病率，并提供了对治疗耐药机制的见解。了解这些基因的高耐药率可能有助于开发更有效的BCC靶向治疗方法。
